Abstract
The study examined in simulations the interaction between a muscle relaxant and an antagonist that binds the free molecules of the relaxant, as experimentally demonstrated for rocuronium and sugammadex. The hypothetical muscle relaxant D and the hypothetical antagonist X were assigned pharmacokinetic properties to define the time course of their concentrations in plasma, and pharmacodynamic properties to define binding of D to either X or the receptors at the motor end plates. D, X, and their complex DX were postulated to diffuse between plasma and the effect compartment. The first and the fourth twitch elicited in sequential trains of four stimuli were evaluated in a model of neuromuscular transmission. The rates of reactions were formulated as differential equations and the equations solved numerically. If the affinity of D for X is comparable to that of D for the postsynaptic receptors, doses of X two to four times larger than the dose of D produce a fast and a complete recovery of the twitches. Smaller doses of X or lower affinities of D for X accomplish a slower and only partial recovery. Additionally, the complete restoration of twitch strength within 2 min after the injection of X requires that X and DX diffuse into the effect compartment. The simulations reveal the physicochemical, pharmacokinetic, and pharmacodynamic properties of an antagonist that restores twitch strength by sequestering the free molecules of the muscle relaxant.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Adam JM, Bennett DJ, Bom A, Clark JK, Feilden H, Hutchinson EJ, Palin R, Prosser A, Rees DC, Rosair GM, Stevenson D, Tarver GJ and Zhang MQ (2002). Cyclodextrin-derived host molecules as reversal agents for the neuromuscular blocker rocuronium bromide: synthesis and structure-activity relationships. J Med Chem 45: 1806–1816
Bom A, Bradley M, Cameron K, Clark JK, Van Egmond J, Feilden H, MacLean EJ, Muir AW, Palin R, Rees DC and Zhang M-Q (2002). A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host. Angew Chem (Int Ed Engl) 41: 266–270
Cameron KS, Clark JK, Cooper A, Fielding L, Palin R, Rutherford SJ and Zhang MQ (2002). Modified gamma-cyclodextrins and their rocuronium complexes. Org Lett 4: 3403–3406
Cameron KS, Fielding L, Mason R, Muir AW, Rees DC, Thorn S and Zhang MQ (2002). Anionic cyclophanes as potential reversal agents of muscle relaxants by chemical chelation. Bioorg Med Chem Lett 12: 753–755
Tarver GJ, Grove SJ, Buchanan K, Bom A, Cooke A, Rutherford SJ and Zhang MQ (2002). 2-O-substituted cyclodextrins as reversal agents for the neuromuscular blocker rocuronium bromide. Bioorg Med Chem 10: 1819–1827
Epemolu O, Bom A, Hope F, Mason R (2003) Reversal of neuromuscular blockade and simultaneous increase in plasma rocuronium concentration after the intravenous infusion of the novel reversal agent Org 25969. Anesthesiology 99:632–637; discussion 636A
Hope F and Bom A (2001). Org 25969 reverses rocuronium-induced neuromuscular blockade in the cat without important haemodynamic effect. Eur J Anaesthesiol 18(Suppl 23): 99
Mason R and Bom A (2001). Org 25969 causes selective reversal of neuromuscular block induced by steroidal NMBs in anaesthetized giunea pigs. Eur J Anaesthesiol 18(Suppl 23): 100
Miller S and Bom A (2001). Org 25969 causes selective reversal of neuromuscular blockade induced by steroidal NMBs in the mouise hemi-diapgragm preparation. Eur J Anaesthesiol 18(Suppl 23): 100–101
Booij L, Bom A, van Egmont J and van de Pol F (2001). Neuromuscular blockade induced by steroidal NMBs can be rapidly reversed by Org 25969 in the anaesthetized monkey. Eur J Anaesthesiol 18(Suppl 23): 100
Bom A, Booij LH, de Boer HD, van Egmond J and van de Pol F (2006). Reversal of profound rocuronium neuromuscular blockade by sugammadex in anesthetized rhesus monkeys. Anesthesiology 104: 718–723
Gijsenbergh F, Ramael S, Houwing N and van Iersel T (2005). First human exposure of Org 25969, a novel agent to reverse the action of rocuronium bromide. Anesthesiology 103: 695–703
Shields M, Giovannelli M, Mirakhur RK, Moppett I, Adams J and Hermens Y (2006). Org 25969 (sugammadex), a selective relaxant binding agent for antagonism of prolonged rocuronium-induced neuromuscular block. Br J Anaesth 96: 36–43
Sorgenfrei IF, Norrild K, Larsen PB, Stensballe J, Ostergaard D, Prins ME and Viby-Mogensen J (2006). Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex: a dose-finding and safety study. Anesthesiology 104: 667–674
Suy K, Morias K, Cammu G, Hans P, Heeringa M, Demeyer I and van Duijnhoven WG F (2007). Effective reversal of moderate rocuronium- or vecuronium-induced neuromuscular block with sugammadex, a selective relaxant binding agent. Anesthesiology 106: 283–288
Groudine SB, Soto R, Lien C, Drover D and Roberts K (2007). A randomized, dose-finding, phase II study of the selective relaxant binding drug, Sugammadex, capable of safely reversing profound rocuronium-induced neuromuscular block. Anesth Analg 104: 555–562
Hunter JM and Flockton EA (2006). The doughnut and the hole: a new pharmacological concept for anaesthetists. Br J Anaesth 97: 123–126
Kopman AF (2006). Sugammadex: a revolutionary approach to neuromuscular antagonism. Anesthesiology 104: 631–633
Miller RD (2007). Sugammadex: an opportunity to change the practice of anesthesiology?. Anesth Analg 104: 477–478
Naguib M (2007). Sugammadex: another milestone in clinical neuromuscular pharmacology. Anesth Analg 104: 575–581
Bom A, Bradley M, Cameron K, Clark JK, Feilden H, MacLean EJ, Muir AW, Palin R, Rees DC, Zhang MQ and van Egmond J (2002). A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host. Angew Chem Int Ed Engl 41: 266–270
Nigrovic V, Bhatt SB, Amann A (2006) First human exposure to Org 25969. Anesthesiology 105:427; author reply 427
Levitt DG (2003). The pharmacokinetics of the interstitial space in humans. BMC Clin Pharmacol 3: 3
Nigrovic V, Anton A and Bengez R (2004). Analysis of the pharmacodynamic parameters in a model for neuromuscular block. Med Sci Monit 10: BR468–BR476
Fambrough DM, Drachman DB and Satyamurti S (1973). Neuromuscular junction in myasthenia gravis: decreased acetylcholine receptors. Science 182: 293–295
Bhatt SB, Amann A and Nigrovic V (2006). Modeling of twitch fade based on slow interaction of nondepolarizing muscle relaxants with the presynaptic receptors. J Pharmacokinet Pharmacodyn 33: 461–483
Nigrovic V and Amann A (2003). Competition between acetylcholine and a nondepolarizing muscle relaxant for binding to the postsynaptic receptors at the motor end plate: simulation of twitch strength and neuromuscular block. J Pharmacokinet Pharmacodyn 30: 23–51
Kopman AF, Yee PS and Neuman GG (1997). Relationship of the train-of-four fade ratio to clinical signs and symptoms of residual paralysis in awake volunteers. Anesthesiology 86: 765–771
Bom A, Booij LH, de Boer HD, van Egmond J and van de Pol F (2006). Sugammadex, a new reversal agent for neuromuscular block induced by rocuronium in the anaesthetized Rhesus monkey. Br J Anaesth 96: 473–479
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Nigrovic, V., Bhatt, S.B. & Amann, A. Simulation of the reversal of neuromuscular block by sequestration of the free molecules of the muscle relaxant. J Pharmacokinet Pharmacodyn 34, 771–788 (2007). https://doi.org/10.1007/s10928-007-9068-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10928-007-9068-y